BioCentury
ARTICLE | Company News

Champions Oncology, Teva deal

February 25, 2013 8:00 AM UTC

Champions (formerly Champions Biotechnology Inc.) received a one-time $880,000 cash payment from Teva for completing an analysis of the efficacy and differentiation of Teva's CEP-32496. Teva plans t...